trastuzumab
Daiichi Sankyo,AstraZeneca,Roche
['estimate ', 'breast', 'trastuzumab']
do all patients with her2+ breast cancer after neoadjuvant therapy and residual disease need adjuvant t-dm1? we try to provide a more precise estimate of 3y dfs in patients treated with trastuzumab alone from data in randomized trials. 
Medical Oncologist, Clinical Research Fellow Breast, GU and Acute Oncology at Princess Margaret Cancer Center. Alumni of AIIMS, New Delhi